Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study

AK. Maniatis, M. Carakushansky, S. Galcheva, G. Prakasam, LA. Fox, A. Dankovcikova, J. Loftus, AA. Palladino, M. de Los Angeles Resa, C. Turich Taylor, MT. Dattani, J. Lebl

. 2022 ; 6 (10) : bvac117. [pub] 20220910

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22023328

Context: Somatrogon is a long-acting recombinant human growth hormone treatment developed as a once-weekly treatment for pediatric patients with growth hormone deficiency (GHD). Objective: Evaluate patient and caregiver perceptions of the treatment burden associated with the once-weekly somatrogon injection regimen vs a once-daily Somatropin injection regimen. Methods: Pediatric patients (≥3 to <18 years) with GHD receiving once-daily somatropin at enrollment were randomized 1:1 to Sequence 1 (12 weeks of once-daily Somatropin, then 12 weeks of once-weekly somatrogon) or Sequence 2 (12 weeks of once-weekly somatrogon, then 12 weeks of once-daily Somatropin). Treatment burden was assessed using validated questionnaires completed by patients and caregivers. The primary endpoint was the difference in mean overall life interference (LI) total scores after each 12-week treatment period (somatrogon vs Somatropin), as assessed by questionnaires. Results: Of 87 patients randomized to Sequence 1 (n = 43) or 2 (n = 44), 85 completed the study. Once-weekly somatrogon had a significantly lower treatment burden than once-daily Somatropin, based on mean overall LI total scores after somatrogon (8.63) vs Somatropin (24.13) treatment (mean difference -15.49; 2-sided 95% CI -19.71, -11.27; P < .0001). Once-weekly somatrogon was associated with greater convenience, higher satisfaction with treatment experience, and less LI. The incidence of treatment-emergent adverse events (TEAEs) for Somatropin and somatrogon was 44.2% and 54.0%, respectively. No severe or serious AEs were reported. Conclusion: In pediatric patients with GHD, once-weekly somatrogon had a lower treatment burden and was associated with a more favorable treatment experience than once-daily Somatropin.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023328
003      
CZ-PrNML
005      
20221031095321.0
007      
ta
008      
221010s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1210/jendso/bvac117 $2 doi
035    __
$a (PubMed)36101713
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Maniatis, Aristides K $u Rocky Mountain Pediatric Endocrinology, Centennial, CO 80112, USA $1 https://orcid.org/0000000267058579
245    10
$a Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study / $c AK. Maniatis, M. Carakushansky, S. Galcheva, G. Prakasam, LA. Fox, A. Dankovcikova, J. Loftus, AA. Palladino, M. de Los Angeles Resa, C. Turich Taylor, MT. Dattani, J. Lebl
520    9_
$a Context: Somatrogon is a long-acting recombinant human growth hormone treatment developed as a once-weekly treatment for pediatric patients with growth hormone deficiency (GHD). Objective: Evaluate patient and caregiver perceptions of the treatment burden associated with the once-weekly somatrogon injection regimen vs a once-daily Somatropin injection regimen. Methods: Pediatric patients (≥3 to <18 years) with GHD receiving once-daily somatropin at enrollment were randomized 1:1 to Sequence 1 (12 weeks of once-daily Somatropin, then 12 weeks of once-weekly somatrogon) or Sequence 2 (12 weeks of once-weekly somatrogon, then 12 weeks of once-daily Somatropin). Treatment burden was assessed using validated questionnaires completed by patients and caregivers. The primary endpoint was the difference in mean overall life interference (LI) total scores after each 12-week treatment period (somatrogon vs Somatropin), as assessed by questionnaires. Results: Of 87 patients randomized to Sequence 1 (n = 43) or 2 (n = 44), 85 completed the study. Once-weekly somatrogon had a significantly lower treatment burden than once-daily Somatropin, based on mean overall LI total scores after somatrogon (8.63) vs Somatropin (24.13) treatment (mean difference -15.49; 2-sided 95% CI -19.71, -11.27; P < .0001). Once-weekly somatrogon was associated with greater convenience, higher satisfaction with treatment experience, and less LI. The incidence of treatment-emergent adverse events (TEAEs) for Somatropin and somatrogon was 44.2% and 54.0%, respectively. No severe or serious AEs were reported. Conclusion: In pediatric patients with GHD, once-weekly somatrogon had a lower treatment burden and was associated with a more favorable treatment experience than once-daily Somatropin.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Carakushansky, Mauri $u Nemours Children's Hospital, Orlando, FL 32827, USA
700    1_
$a Galcheva, Sonya $u UMHAT "St. Marina", Varna, Bulgaria
700    1_
$a Prakasam, Gnanagurudasan $u Sutter Medical Center and Center of Excellence in Diabetes and Endocrinology, Sacramento, CA 95821, USA $1 https://orcid.org/0000000248657867
700    1_
$a Fox, Larry A $u Nemours Children's Health, Jacksonville, FL 32207, USA
700    1_
$a Dankovcikova, Adriana $u Children's Faculty Hospital Košice, Košice, Slovakia
700    1_
$a Loftus, Jane $u Pfizer Ltd, Tadworth, UK
700    1_
$a Palladino, Andrew A $u Pfizer Inc, Collegeville, PA 19426,USA
700    1_
$a de Los Angeles Resa, Maria $u Pfizer Inc, New York, NY 10017, USA
700    1_
$a Turich Taylor, Carrie $u Pfizer Inc, New York, NY 10017, USA
700    1_
$a Dattani, Mehul T $u UCL Great Ormond Street Institute of Child Health, London, UK $1 https://orcid.org/0000000203655809
700    1_
$a Lebl, Jan $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
773    0_
$w MED00209724 $t Journal of the Endocrine Society $x 2472-1972 $g Roč. 6, č. 10 (2022), s. bvac117
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36101713 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095319 $b ABA008
999    __
$a ind $b bmc $g 1853812 $s 1174616
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 6 $c 10 $d bvac117 $e 20220910 $i 2472-1972 $m Journal of the Endocrine Society $n J Endocr Soc $x MED00209724
LZP    __
$a Pubmed-20221010

Find record

Citation metrics

Archiving options